PEGylation, successful approach to drug delivery.

By F. Veronese, G. Pasut. Drug Discovery Today, 2005

2,109 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Advances in Oral Drug Delivery (2021, background): “In addition, the inhibitory activity of efflux pump by several conjugates such as PEG-based detergents have been reported (Veronese and Pasut, 2005).”
Current advances and future perspectives in extrusion-based bioprinting. (2016, background): “, pegfilgrastim, pegvisomant and methoxy polyethylene glycol-epoetin beta [114]) for internal use and can be crosslinked using physical, ionic or covalent crosslinks [115].”
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. (2016, neutral): “Adagen®, pegadamase 96-126 5 [11-17] Patient d”
Post-translational modifications in the context of therapeutic proteins (2006, positive): “PEGylation may be achieved by several well-characterized enzymatic or direct chemical approache”
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come (2016, background): “These investigators conjugated PEG to proteins (Abuchowski et al., 1977) and later demonstrated that PEGylation helped reduce the immunogenicity of therapeutics aswell as improve their safety and efficacy (Veronese, 2001; Veronese and Pasut, 2005).”